RESEARCH
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapyA systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay sensitivity and tumor heterogeneity. (J Gastrointest Oncol)